Bladder cancer is the fourth most common malignancy in males. It can present across the
whole continuum of severity, from mild through well-differentiated disease to extremely …

Due to its tendency to recur and acquire chemoresistance quickly, bladder cancer (BC)
remains to be an elusive and difficult disease. Patients with recurrent and chemoresistant …

Simple Summary RAS oncoproteins are considered undruggable cancer targets. Nearly
15% of cases of bladder cancer have a mutation of HRAS. The active HRAS contributes to …

Simple Summary Our previous studies characterized that FXR overexpression results in the
inhibition of migratory, adhesive and angiogenic abilities through the proteosome …

Cisplatin-based chemotherapy is the first-line therapy for bladder cancer. However, cisplatin
resistance has been associated with the recurrence of bladder cancer. Previous studies …

Fibroblast growth factor receptor 3 (FGFR3) belongs to a family of receptor tyrosine kinases
that control cell proliferation, differentiation, and survival. Aberrant activation of FGFR3 via …

Background The standard treatment for patients with advanced transitional cell carcinoma of
the bladder is platin based chemotherapy. Only approximately 50% of the patients respond …

Cisplatin is an important chemotherapeutic agent against metastatic bladder cancer, but
resistance often limits its usage. With the recent recognition of lipid metabolic alterations in …

Cisplatin is currently the most effective antitumor agent available against bladder cancer.
However, a majority of patients eventually relapse with cisplatin-resistant disease …

Protein S-palmitoylation is a powerful post-translational modification that regulates protein
trafficking, localization, turnover, and signal transduction. Palmitoylation controls several …